PITTSBURGH, Pa.--(BUSINESS WIRE)--StageMark, Inc., a cell analysis company developing innovative research and diagnostic products and services for autoimmune diseases, announced today that it had completed a Series B Convertible Preferred Stock financing totaling approximately $1.6 million in cash and debt conversion. The financing was led by the BioAdvance Ventures, an early stage venture fund managed by Quaker BioVentures, and the University City Science Center (UCSC). Previous investors, BlueTree Capital Partners, Innovation Works, Meyer Ventures and the Pittsburgh Life Sciences Greenhouse, also participated in the offering.
